{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:59:16Z","timestamp":1790369956172,"version":"4.1.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40265-026-02383-1","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:59:56Z","timestamp":1789523996000},"page":"1577-1597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibiotic-Refractory Chronic Pouchitis After Ileal Pouch-Anal Anastomosis: Current and Emerging Therapeutic Strategies"],"prefix":"10.1007","volume":"86","author":[{"given":"Ilaria","family":"Faggiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Sedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-9948","authenticated-orcid":false,"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"10401","key":"2383_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402(10401):571\u201384.","journal-title":"Lancet"},{"issue":"10","key":"2383_CR2","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.cgh.2020.10.039","volume":"19","author":"L Tsai","year":"2021","unstructured":"Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn\u2019s disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol. 2021;19(10):2031-45 e11.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2383_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.dld.2022.08.039","volume":"55","author":"N Dai","year":"2023","unstructured":"Dai N, Haidar O, Askari A, Segal JP. Colectomy rates in ulcerative colitis: a systematic review and meta-analysis. Dig Liver Dis. 2023;55(1):13\u201320.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"2383_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/codi.15985","volume":"24","author":"PT Kroner","year":"2022","unstructured":"Kroner PT, Merchea A, Colibaseanu D, Picco MF, Farraye FA, Stocchi L. The use of ileal pouch-anal anastomosis in patients with ulcerative colitis from 2009 to 2018. Colorectal Dis. 2022;24(3):308\u201313.","journal-title":"Colorectal Dis"},{"issue":"11","key":"2383_CR5","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/DCR.0000000000003894","volume":"68","author":"J Zuckerman","year":"2025","unstructured":"Zuckerman J, de Buck van Overstraeten A, Melmed GY, Mustain WC, Scow JS, Otterson MF, et al. Improvement in functional outcomes following ileal pouch-anal anastomosis: results from the United States ileal pouch-anal anastomosis study. Dis Colon Rectum. 2025;68(11):1315\u201326.","journal-title":"Dis Colon Rectum"},{"key":"2383_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf103","author":"M Kayal","year":"2025","unstructured":"Kayal M, Bislenghi G, Adamina M, Ardalan ZS, Avellaneda N, de Buck van Overstraeten A, et al. ECCO topical review on pouch disorders. J Crohns Colitis. 2025. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf103.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"2383_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1053\/j.gastro.2019.10.001","volume":"158","author":"V Dubinsky","year":"2020","unstructured":"Dubinsky V, Reshef L, Bar N, Keizer D, Golan N, Rabinowitz K, et al. Predominantly antibiotic-resistant intestinal microbiome persists in patients with pouchitis who respond to antibiotic therapy. Gastroenterology. 2020;158(3):610-24 e13.","journal-title":"Gastroenterology"},{"issue":"1","key":"2383_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2023.10.015","volume":"166","author":"EL Barnes","year":"2024","unstructured":"Barnes EL, Agrawal M, Syal G, Ananthakrishnan AN, Cohen BL, Haydek JP, et al. AGA clinical practice guideline on the management of pouchitis and inflammatory pouch disorders. Gastroenterology. 2024;166(1):59\u201385.","journal-title":"Gastroenterology"},{"issue":"9","key":"2383_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10151-022-02617-w","volume":"26","author":"SH Emile","year":"2022","unstructured":"Emile SH, Khan SM, Silva-Alvarenga E, Garoufalia Z, Wexner SD. A systematic review and meta-analysis of the outcome of ileal pouch-anal anastomosis in patients with ulcerative colitis versus patients with familial adenomatous polyposis. Tech Coloproctol. 2022;26(9):691\u2013705.","journal-title":"Tech Coloproctol"},{"issue":"11","key":"2383_CR10","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/DCR.0b013e3181f22635","volume":"53","author":"R Sehgal","year":"2010","unstructured":"Sehgal R, Berg A, Hegarty JP, Kelly AA, Lin Z, Poritz LS, et al. NOD2\/CARD15 mutations correlate with severe pouchitis after ileal pouch-anal anastomosis. Dis Colon Rectum. 2010;53(11):1487\u201394.","journal-title":"Dis Colon Rectum"},{"issue":"10","key":"2383_CR11","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1136\/gutjnl-2011-301957","volume":"62","author":"AD Tyler","year":"2013","unstructured":"Tyler AD, Milgrom R, Stempak JM, Xu W, Brumell JH, Muise AM, et al. The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis. Gut. 2013;62(10):1433\u20139.","journal-title":"Gut"},{"issue":"40","key":"2383_CR12","doi-asserted-by":"publisher","first-page":"8929","DOI":"10.3748\/wjg.v22.i40.8929","volume":"22","author":"KY Li","year":"2016","unstructured":"Li KY, Wang JL, Wei JP, Gao SY, Zhang YY, Wang LT, et al. Fecal microbiota in pouchitis and ulcerative colitis. World J Gastroenterol. 2016;22(40):8929\u201339.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2383_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/gutjnl-2015-309398","volume":"66","author":"K Machiels","year":"2017","unstructured":"Machiels K, Sabino J, Vandermosten L, Joossens M, Arijs I, de Bruyn M, et al. Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC. Gut. 2017;66(1):79\u201388.","journal-title":"Gut"},{"key":"2383_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113243","author":"O Palmieri","year":"2021","unstructured":"Palmieri O, Castellana S, Biscaglia G, Panza A, Latiano A, Fontana R, et al. Microbiome analysis of mucosal ileoanal pouch in ulcerative colitis patients revealed impairment of the pouches immunometabolites. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10113243.","journal-title":"Cells"},{"issue":"7","key":"2383_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41575-024-00920-5","volume":"21","author":"B Shen","year":"2024","unstructured":"Shen B. Pouchitis: pathophysiology and management. Nat Rev Gastroenterol Hepatol. 2024;21(7):463\u201376.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"2383_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1053\/j.gastro.2015.05.041","volume":"149","author":"L Reshef","year":"2015","unstructured":"Reshef L, Kovacs A, Ofer A, Yahav L, Maharshak N, Keren N, et al. Pouch inflammation is associated with a decrease in specific bacterial taxa. Gastroenterology. 2015;149(3):718\u201327.","journal-title":"Gastroenterology"},{"issue":"5","key":"2383_CR17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/DCR.0000000000003163","volume":"67","author":"JP Knowles","year":"2024","unstructured":"Knowles JP, Church J. Normal ileal mucus is inadequate for epithelial protection in ileal pouch mucosa. Dis Colon Rectum. 2024;67(5):635\u201344.","journal-title":"Dis Colon Rectum"},{"issue":"7","key":"2383_CR18","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/ibd\/izab209","volume":"28","author":"N Bar","year":"2022","unstructured":"Bar N, Avraham Y, Dubinsky V, Cohen NA, Weiss GA, Banon L, et al. Long-term antibiotic treatment in pouchitis-patterns of use and safety. Inflamm Bowel Dis. 2022;28(7):1027\u201333.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"2383_CR19","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/ecco-jcc\/jjab041","volume":"15","author":"M de Krijger","year":"2021","unstructured":"de Krijger M, Wildenberg ME, Mookhoek A, Verheul S, de Jonge WJ, Ponsioen CY. Expression of MAdCAM-1 and gut-homing T cells in inflamed pouch mucosa. J Crohns Colitis. 2021;15(9):1491\u20139.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"2383_CR20","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1053\/j.gastro.2020.12.030","volume":"160","author":"JC Devlin","year":"2021","unstructured":"Devlin JC, Axelrad J, Hine AM, Chang S, Sarkar S, Lin JD, et al. Single-cell transcriptional survey of ileal-anal pouch immune cells from ulcerative colitis patients. Gastroenterology. 2021;160(5):1679\u201393.","journal-title":"Gastroenterology"},{"issue":"5","key":"2383_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1136\/gutjnl-2014-307387","volume":"64","author":"H Yanai","year":"2015","unstructured":"Yanai H, Ben-Shachar S, Baram L, Elad H, Gitstein G, Brazowski E, et al. Gene expression alterations in ulcerative colitis patients after restorative proctocolectomy extend to the small bowel proximal to the pouch. Gut. 2015;64(5):756\u201364.","journal-title":"Gut"},{"issue":"6","key":"2383_CR22","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s10350-004-6297-7","volume":"45","author":"UA Heuschen","year":"2002","unstructured":"Heuschen UA, Allemeyer EH, Hinz U, Autschbach F, Uehlein T, Herfarth C, et al. Diagnosing pouchitis: comparative validation of two scoring systems in routine follow-up. Dis Colon Rectum. 2002;45(6):776\u201386 (discussion 86-8).","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"2383_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0025-6196(12)61634-6","volume":"69","author":"WJ Sandborn","year":"1994","unstructured":"Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc. 1994;69(5):409\u201315.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2383_CR24","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s10350-004-6652-8","volume":"46","author":"B Shen","year":"2003","unstructured":"Shen B, Achkar JP, Connor JT, Ormsby AH, Remzi FH, Bevins CL, et al. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum. 2003;46(6):748\u201353.","journal-title":"Dis Colon Rectum"},{"issue":"4","key":"2383_CR25","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/ibd\/izab124","volume":"28","author":"R Sedano","year":"2022","unstructured":"Sedano R, Nguyen TM, Almradi A, Rieder F, Parker CE, Shackelton LM, et al. Disease activity indices for pouchitis: a systematic review. Inflamm Bowel Dis. 2022;28(4):622\u201338.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2383_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cgh.2021.02.010","volume":"20","author":"S Akiyama","year":"2022","unstructured":"Akiyama S, Ollech JE, Rai V, Glick LR, Yi Y, Traboulsi C, et al. Endoscopic phenotype of the j pouch in patients with inflammatory bowel disease: a new classification for pouch outcomes. Clin Gastroenterol Hepatol. 2022;20(2):293-302 e9.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2383_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.cgh.2025.06.030","volume":"24","author":"R Sedano","year":"2026","unstructured":"Sedano R, Ma C, Hogan M, Silverberg MS, Zou G, D\u2019Haens GR, et al. Development and external validation of an endoscopic and histologic pouchitis assessment tool: the Atlantic pouchitis index. Clin Gastroenterol Hepatol. 2026;24(2):512\u201324.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"2383_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.crohns.2013.12.001","volume":"8","author":"P Gionchetti","year":"2014","unstructured":"Gionchetti P, Calabrese C, Calafiore A, Pratico C, Poggioli G, Laureti S, et al. Oral beclomethasone dipropionate in chronic refractory pouchitis. J Crohns Colitis. 2014;8(7):649\u201353.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"2383_CR29","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/j.1365-2036.2007.03306.x","volume":"25","author":"P Gionchetti","year":"2007","unstructured":"Gionchetti P, Rizzello F, Poggioli G, Pierangeli F, Laureti S, Morselli C, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther. 2007;25(10):1231\u20136.","journal-title":"Aliment Pharmacol Ther"},{"key":"2383_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002913.pub3","author":"ME Kuenzig","year":"2014","unstructured":"Kuenzig ME, Rezaie A, Seow CH, Otley AR, Steinhart AH, Griffiths AM, et al. Budesonide for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD002913.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2383_CR31","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/apt.14334","volume":"46","author":"CP Selinger","year":"2017","unstructured":"Selinger CP, Parkes GC, Bassi A, Fogden E, Hayee B, Limdi JK, et al. A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(10):964\u201373.","journal-title":"Aliment Pharmacol Ther"},{"issue":"13","key":"2383_CR32","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2208450","volume":"388","author":"S Travis","year":"2023","unstructured":"Travis S, Silverberg MS, Danese S, Gionchetti P, Lowenberg M, Jairath V, et al. Vedolizumab for the treatment of chronic pouchitis. N Engl J Med. 2023;388(13):1191\u2013200.","journal-title":"N Engl J Med"},{"issue":"2","key":"2383_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cgh.2024.06.037","volume":"23","author":"V Jairath","year":"2025","unstructured":"Jairath V, Feagan BG, Silverberg MS, Danese S, Gionchetti P, Lowenberg M, et al. Mucosal healing with vedolizumab in patients with chronic pouchitis: EARNEST, a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2025;23(2):321-30 e3.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2383_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/00365521.2019.1569718","volume":"54","author":"MD Kjaer","year":"2019","unstructured":"Kjaer MD, Qvist N, Nordgaard-Lassen I, Christensen LA, Kjeldsen J. Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial. Scand J Gastroenterol. 2019;54(2):188\u201393.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"2383_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.14309\/ajg.0000000000003136","volume":"120","author":"G Syal","year":"2025","unstructured":"Syal G, Barnes E, Raffals L, Al Kazzi E, Haydek J, Agrawal M, et al. Medical therapies for prevention and treatment of inflammatory pouch disorders-a systematic review and meta-analysis. Am J Gastroenterol. 2025;120(1):135\u201350.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2383_CR36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/MCG.0000000000001550","volume":"55","author":"S Chandan","year":"2021","unstructured":"Chandan S, Mohan BP, Kumar A, Khan SR, Chandan OC, Kassab LL, et al. Safety and efficacy of biological therapy in chronic antibiotic refractory pouchitis: a systematic review with meta-analysis. J Clin Gastroenterol. 2021;55(6):481\u201391.","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"2383_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/apt.13905","volume":"45","author":"JP Segal","year":"2017","unstructured":"Segal JP, Ding NS, Worley G, McLaughlin S, Preston S, Faiz OD, et al. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. Aliment Pharmacol Ther. 2017;45(5):581\u201392.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2383_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/MCG.0000000000001828","volume":"58","author":"G Godoy-Brewer","year":"2024","unstructured":"Godoy-Brewer G, Salem G, Limketkai B, Selaru FM, Grossen A, Policarpo T, et al. Use of biologics for the treatment of inflammatory conditions of the pouch: a systematic review. J Clin Gastroenterol. 2024;58(2):183\u201394.","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"2383_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/apt.17568","volume":"58","author":"L Alphonsus","year":"2023","unstructured":"Alphonsus L, De Silva TA, Ma C, MacDonald JK, Hanzel J, Beaton M, et al. Systematic review and meta-analysis of randomised controlled trials: medical therapies for the treatment and prevention of pouchitis. Aliment Pharmacol Ther. 2023;58(3):268\u201382.","journal-title":"Aliment Pharmacol Ther"},{"key":"2383_CR40","doi-asserted-by":"publisher","first-page":"175628482614223","DOI":"10.1177\/17562848261422373","volume":"19","author":"F Mesonero","year":"2026","unstructured":"Mesonero F, Zabana Y, Fernandez-Clotet A, Leo-Carnerero E, Caballol B, Nunez A, et al. Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU. Ther Adv Gastroenterol. 2026;19:17562848261422372.","journal-title":"Ther Adv Gastroenterol"},{"key":"2383_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-026-09804-x","author":"Y Uchitel","year":"2026","unstructured":"Uchitel Y, Cohen NA, Hirsch A, Tulchinsky H, Zemel M, Har-Shefi T, et al. Comparative effectiveness of biologic therapies in chronic pouchitis and Crohn\u2019s-like disease of the pouch: a bi-center retrospective cohort study. Dig Dis Sci. 2026. https:\/\/doi.org\/10.1007\/s10620-026-09804-x.","journal-title":"Dig Dis Sci"},{"issue":"11","key":"2383_CR42","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1093\/ibd\/izaf146","volume":"31","author":"S Park","year":"2025","unstructured":"Park S, Keyashian K, Ho A, Limsui D, Frost S, Vazquez R, et al. Efficacy and safety of ustekinumab and vedolizumab for Crohn\u2019s disease of the pouch. Inflamm Bowel Dis. 2025;31(11):3142\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"2383_CR43","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1016\/j.dld.2025.10.028","volume":"57","author":"M Fischman","year":"2025","unstructured":"Fischman M, Godny L, Friedenberg A, Barkan R, White I, Wasserberg N, et al. Drug persistence of first- and advanced-line therapy for chronic inflammatory pouch disorders: a prospective cohort spanning sequential treatment lines. Dig Liver Dis. 2025;57(12):2370\u20135.","journal-title":"Dig Liver Dis"},{"key":"2383_CR44","first-page":"14309","volume":"10","author":"EL Barnes","year":"2025","unstructured":"Barnes EL, Raffals L, Qazi T, Deepak P, Chang S, Beniwal-Patel P, et al. A prospective comparison of ustekinumab and antitumor necrosis factor alpha therapy in the treatment of Crohn\u2019s-like disease of the pouch. Am J Gastroenterol. 2025;10:14309.","journal-title":"Am J Gastroenterol"},{"key":"2383_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1630678","volume":"16","author":"L Gimeno-Pitarch","year":"2025","unstructured":"Gimeno-Pitarch L, Cespedes-Martinez E, Ferreiro-Iglesias R, Martin-Arranz MD, Sicilia B, Lorca I, et al. Real-world effectiveness of vedolizumab in refractory pouchitis: a focus on biomarker changes during intravenous to subcutaneous transition (POUCHIVED study). Front Immunol. 2025;16:1630678.","journal-title":"Front Immunol"},{"key":"2383_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15052053","author":"I Ghersin","year":"2026","unstructured":"Ghersin I, Argyriou O, Sahnan K, Warusavitarne J, Hart AL. A pilot study of the effectiveness and safety of subcutaneous infliximab in chronic inflammatory pouch conditions: the St. Mark\u2019s experience. J Clin Med. 2026. https:\/\/doi.org\/10.3390\/jcm15052053.","journal-title":"J Clin Med"},{"issue":"5","key":"2383_CR47","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","volume":"167","author":"SB Hanauer","year":"2024","unstructured":"Hanauer SB, Sands BE, Schreiber S, Danese S, Klopocka M, Kierkus J, et al. Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY). Gastroenterology. 2024;167(5):919\u201333.","journal-title":"Gastroenterology"},{"issue":"3","key":"2383_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","volume":"391","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D\u2019Haens G, Ferrante M, et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease. N Engl J Med. 2024;391(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"10501","key":"2383_CR49","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(25)00681-6","volume":"406","author":"R Panaccione","year":"2025","unstructured":"Panaccione R, Feagan BG, Afzali A, Rubin DT, Reinisch W, Panes J, et al. Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn\u2019s disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. Lancet. 2025;406(10501):358\u201375.","journal-title":"Lancet"},{"key":"2383_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.10.026","author":"M Kayal","year":"2025","unstructured":"Kayal M, Jimenez D, Huang J, Spencer EA. Comparable 12-week and superior 24-week remission with risankizumab vs ustekinumab for Crohn\u2019s-like disease of the pouch. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.10.026.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2383_CR51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/2050640615593681","volume":"4","author":"T Greuter","year":"2016","unstructured":"Greuter T, Biedermann L, Rogler G, Sauter B, Seibold F. Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: a case series. United Eur Gastroenterol J. 2016;4(1):97\u2013104.","journal-title":"United Eur Gastroenterol J"},{"issue":"3","key":"2383_CR52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2036.2004.01863.x","volume":"19","author":"P Miner","year":"2004","unstructured":"Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther. 2004;19(3):281\u20136.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"2383_CR53","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/j.dld.2025.09.007","volume":"57","author":"A Garg","year":"2025","unstructured":"Garg A, Moond V, Bassi M, Santharaman A, Recinos-Arenas L, Broder A. Exploring the role of tofacitinib in managing chronic pouchitis: a systematic review and meta-analysis. Dig Liver Dis. 2025;57(12):2279\u201385.","journal-title":"Dig Liver Dis"},{"issue":"10S","key":"2383_CR54","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.14309\/01.ajg.0000860812.30174.a5","volume":"117","author":"R Dalal","year":"2022","unstructured":"Dalal R, Bains K, Marcus J, McClure E, Allegretti JR. S1043\u2003Tofacitinib for the treatment of pouch-related disorders: a case series. Am J Gastroenterol. 2022;117(10S):e756\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2383_CR55","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/ecco-jcc\/jjad194","volume":"18","author":"DG Ribaldone","year":"2024","unstructured":"Ribaldone DG, Testa G, Verstockt B, Molnar T, Savarino E, Schmidt C, et al. Treatment of antibiotic refractory chronic pouchitis with JAK inhibitors and S1P receptor modulators: an ECCO CONFER multicentre case series. J Crohns Colitis. 2024;18(5):720\u20136.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2383_CR56","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001245","volume":"11","author":"N Lan","year":"2024","unstructured":"Lan N, Shen B. Efficacy and safety of upadacitinib in the treatment of chronic pouchitis, cuffitis, and Crohn\u2019s disease of the pouch. ACG Case Rep J. 2024;11(1):e01245.","journal-title":"ACG Case Rep J"},{"issue":"2","key":"2383_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/jcc5.70026","volume":"1","author":"M Uchino","year":"2026","unstructured":"Uchino M, Horio Y, Kuwahara R, Kusunoki K, Nagano K, Nomura K, et al. Efficacy of filgotinib for treating chronic antibiotic-dependent pouchitis: a pilot study. JCC Plus. 2026;1(2):e70026.","journal-title":"JCC Plus"},{"issue":"4","key":"2383_CR58","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.cgh.2025.07.009","volume":"24","author":"HH Lee","year":"2026","unstructured":"Lee HH, Yuan Y, Boland BS, Chang JT, Jairath V, Singh S. Efficacy of advanced therapies in achieving remission by disease location in Crohn\u2019s disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2026;24(4):923\u201331.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2383_CR59","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.14309\/ajg.0000000000002801","volume":"119","author":"H Herfarth","year":"2024","unstructured":"Herfarth H, Long MD, Hansen JJ, Anderson C, English E, Buse JB, et al. Efficacy and safety of liraglutide in patients with an ileal pouch-anal anastomosis and chronic high bowel frequency: a placebo-controlled, crossover, proof-of-concept study. Am J Gastroenterol. 2024;119(9):1935\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2383_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000497042","volume":"4","author":"H Herfarth","year":"2019","unstructured":"Herfarth H, Barnes EL, Long MD, Isaacs KL, Leith T, Silverstein M, et al. Combined endoscopic and oral fecal microbiota transplantation in patients with antibiotic-dependent pouchitis: low clinical efficacy due to low donor microbial engraftment. Inflamm Intest Dis. 2019;4(1):1\u20136.","journal-title":"Inflamm Intest Dis"},{"issue":"1","key":"2383_CR61","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjad120","volume":"18","author":"S Zaman","year":"2024","unstructured":"Zaman S, Akingboye A, Mohamedahmed AYY, Peterknecht E, Bhattacharya P, El-Asrag ME, et al. Faecal microbiota transplantation [FMT] in the treatment of chronic refractory pouchitis: a systematic review and meta-analysis. J Crohns Colitis. 2024;18(1):144\u201361.","journal-title":"J Crohns Colitis"},{"issue":"11","key":"2383_CR62","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/ibd\/izab001","volume":"27","author":"EK Karjalainen","year":"2021","unstructured":"Karjalainen EK, Renkonen-Sinisalo L, Satokari R, Mustonen H, Ristimaki A, Arkkila P, et al. Fecal microbiota transplantation in chronic pouchitis: a randomized, parallel, double-blinded clinical trial. Inflamm Bowel Dis. 2021;27(11):1766\u201372.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"2383_CR63","doi-asserted-by":"publisher","first-page":"S-916","DOI":"10.1016\/S0016-5107(26)02350-3","volume":"103","author":"SA Syed","year":"2026","unstructured":"Syed SA, Delungahawatta T, Patel J, Castelli J, Moayyedi P, Surette M, et al. 983 Fecal microbiota transplantation versus placebo for the induction of remission in active pouchitis: a randomized controlled trial. Gastrointest Endosc. 2026;103(5):S-916-S\u22127.","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"2383_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2510464","volume":"17","author":"SJ Kousgaard","year":"2025","unstructured":"Kousgaard SJ, Dall SM, Albertsen M, Nielsen HL, Thorlacius-Ussing O. Fecal microbiota transplantation from a healthy pouch donor for chronic pouchitis: a proof-of-concept study. Gut Microbes. 2025;17(1):2510464.","journal-title":"Gut Microbes"},{"issue":"8","key":"2383_CR65","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/apt.16085","volume":"52","author":"ZS Ardalan","year":"2020","unstructured":"Ardalan ZS, Yao CK, Sparrow MP, Gibson PR. Review article: the impact of diet on ileoanal pouch function and on the pathogenesis of pouchitis. Aliment Pharmacol Ther. 2020;52(8):1323\u201340.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"2383_CR66","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/ibd.20249","volume":"13","author":"C Croagh","year":"2007","unstructured":"Croagh C, Shepherd SJ, Berryman M, Muir JG, Gibson PR. Pilot study on the effect of reducing dietary FODMAP intake on bowel function in patients without a colon. Inflamm Bowel Dis. 2007;13(12):1522\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"2383_CR67","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.clnu.2023.07.023","volume":"42","author":"ZS Ardalan","year":"2023","unstructured":"Ardalan ZS, Livingstone KM, Polzella L, Avakian J, Rohani F, Sparrow MP, et al. Perceived dietary intolerances, habitual intake and diet quality of patients with an ileoanal pouch: associations with pouch phenotype (and behaviour). Clin Nutr. 2023;42(11):2095\u2013108.","journal-title":"Clin Nutr"},{"issue":"10","key":"2383_CR68","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/ecco-jcc\/jjz053","volume":"13","author":"L Godny","year":"2019","unstructured":"Godny L, Maharshak N, Reshef L, Goren I, Yahav L, Fliss-Isakov N, et al. Fruit consumption is associated with alterations in microbial composition and lower rates of pouchitis. J Crohns Colitis. 2019;13(10):1265\u201372.","journal-title":"J Crohns Colitis"},{"issue":"38","key":"2383_CR69","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.3748\/wjg.v19.i38.6458","volume":"19","author":"O Ianco","year":"2013","unstructured":"Ianco O, Tulchinsky H, Lusthaus M, Ofer A, Santo E, Vaisman N, et al. Diet of patients after pouch surgery may affect pouch inflammation. World J Gastroenterol. 2013;19(38):6458\u201364.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2383_CR70","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/ibd\/izaa245","volume":"27","author":"B Hasan","year":"2021","unstructured":"Hasan B, Yim Y, Ur Rashid M, Khalid RA, Sarvepalli D, Castaneda D, et al. Hyperbaric oxygen therapy in chronic inflammatory conditions of the pouch. Inflamm Bowel Dis. 2021;27(7):965\u201370.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"2383_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/codi.70398","volume":"28","author":"AF Hammad","year":"2026","unstructured":"Hammad AF, Erkaya M, Hull TL, Floruta C, Spivak AR, Kanters A, et al. Impact of hyperbaric oxygen therapy on complex perineal fistula healing. Colorectal Dis. 2026;28(3):e70398.","journal-title":"Colorectal Dis"},{"issue":"7","key":"2383_CR72","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1111\/codi.16589","volume":"25","author":"AP Ricardo","year":"2023","unstructured":"Ricardo AP, Kayal M, Plietz MC, Khaitov S, Sylla P, Dubinsky MC, et al. Predictors of pouch failure: a tertiary care inflammatory bowel disease centre experience. Colorectal Dis. 2023;25(7):1469\u201378.","journal-title":"Colorectal Dis"},{"issue":"2","key":"2383_CR73","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00384-021-04067-6","volume":"37","author":"Z Alsafi","year":"2022","unstructured":"Alsafi Z, Snell A, Segal JP. Prevalence of \u0485pouch failure\u2019 of the ileoanal pouch in ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis. 2022;37(2):357\u201364.","journal-title":"Int J Colorectal Dis"},{"key":"2383_CR74","doi-asserted-by":"publisher","DOI":"10.1097\/XCS.0000000000001878","author":"A Alipouriani","year":"2026","unstructured":"Alipouriani A, Chan-Gill H, Uchino T, Lavryk O, Qazi T, Cohen B, et al. 3-Stage vs 2-stage redo ileal pouch-anal anastomosis: setting the stage for successful pouch salvage. J Am Coll Surg. 2026. https:\/\/doi.org\/10.1097\/XCS.0000000000001878.","journal-title":"J Am Coll Surg"},{"issue":"2","key":"2383_CR75","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/XCS.0000000000001878","volume":"243","author":"A Alipouriani","year":"2026","unstructured":"Alipouriani A, Chan-Gill H, Uchino T, Lavryk O, Qazi T, Cohen B, et al. 3-Stage vs 2-stage redo ileal pouch-anal anastomosis: setting the stage for successful pouch salvage. J Am Coll Surg. 2026;243(2):401\u201312.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"2383_CR76","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/ibd\/izae061","volume":"31","author":"T Uchino","year":"2025","unstructured":"Uchino T, Lincango EP, Hernandez Dominguez O, Bhama A, Gorgun E, Kanters A, et al. Rediversion of the failing ileoanal pouch: first step in pouch salvage? Inflamm Bowel Dis. 2025;31(1):105\u201312.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"2383_CR77","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/ueg2.12636","volume":"12","author":"MM Estevinho","year":"2024","unstructured":"Estevinho MM, Yuan Y, Rodriguez-Lago I, Sousa-Pimenta M, Dias CC, Barreiro-de Acosta M, et al. Efficacy and safety of probiotics in IBD: an overview of systematic reviews and updated meta-analysis of randomized controlled trials. United Eur Gastroenterol J. 2024;12(7):960\u201381.","journal-title":"United Eur Gastroenterol J"},{"issue":"8","key":"2383_CR78","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00595-015-1261-9","volume":"46","author":"A Yasueda","year":"2016","unstructured":"Yasueda A, Mizushima T, Nezu R, Sumi R, Tanaka M, Nishimura J, et al. The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis. Surg Today. 2016;46(8):939\u201349.","journal-title":"Surg Today"},{"issue":"5","key":"2383_CR79","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/S0016-5085(03)00171-9","volume":"124","author":"P Gionchetti","year":"2003","unstructured":"Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124(5):1202\u20139.","journal-title":"Gastroenterology"},{"issue":"5","key":"2383_CR80","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ibd.20369","volume":"14","author":"A Pronio","year":"2008","unstructured":"Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis. 2008;14(5):662\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"2383_CR81","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/gut.53.1.108","volume":"53","author":"T Mimura","year":"2004","unstructured":"Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53(1):108\u201314.","journal-title":"Gut"},{"issue":"2","key":"2383_CR82","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1053\/gast.2000.9370","volume":"119","author":"P Gionchetti","year":"2000","unstructured":"Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305\u20139.","journal-title":"Gastroenterology"},{"issue":"8","key":"2383_CR83","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1365-2036.2005.02642.x","volume":"22","author":"B Shen","year":"2005","unstructured":"Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther. 2005;22(8):721\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2383_CR84","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s00595-024-02984-x","volume":"55","author":"Y Koike","year":"2025","unstructured":"Koike Y, Higashi K, Sato Y, Yamashita S, Nagano Y, Shimura T, et al. Preventive effect of Clostridium butyricum MIYAIRI against pouchitis in children with ulcerative colitis. Surg Today. 2025;55(7):986\u201395.","journal-title":"Surg Today"},{"issue":"7","key":"2383_CR85","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/apt.12451","volume":"38","author":"M Persborn","year":"2013","unstructured":"Persborn M, Gerritsen J, Wallon C, Carlsson A, Akkermans LM, Soderholm JD. The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. Aliment Pharmacol Ther. 2013;38(7):772\u201383.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2383_CR86","volume":"5","author":"G Syal","year":"2026","unstructured":"Syal G, Singh S, Barnes EL. Cost effectiveness of the 8-strain probiotic in primary and secondary prophylaxis of pouchitis. Gastroenterol Hepatol Adv. 2026;5(1):100776.","journal-title":"Gastroenterol Hepatol Adv"},{"issue":"7","key":"2383_CR87","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/ibd\/izz227","volume":"26","author":"M Kayal","year":"2020","unstructured":"Kayal M, Plietz M, Rizvi A, Radcliffe M, Riggs A, Yzet C, et al. Inflammatory pouch conditions are common after ileal pouch anal anastomosis in ulcerative colitis patients. Inflamm Bowel Dis. 2020;26(7):1079\u201386.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"2383_CR88","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/ecco-jcc\/jjab025","volume":"15","author":"EL Barnes","year":"2021","unstructured":"Barnes EL, Holubar SD, Herfarth HH. Systematic review and meta-analysis of outcomes after ileal pouch-anal anastomosis in primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis. 2021;15(8):1272\u20138.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2383_CR89","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cgh.2005.10.004","volume":"4","author":"B Shen","year":"2006","unstructured":"Shen B, Fazio VW, Remzi FH, Brzezinski A, Bennett AE, Lopez R, et al. Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4(1):81\u20139 (quiz 2-3).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"2383_CR90","doi-asserted-by":"publisher","DOI":"10.1111\/codi.70267","volume":"27","author":"H Kasashima","year":"2025","unstructured":"Kasashima H, Fukuoka T, Maeda K, Hida K, Ochi S, Takano Y, et al. Analysis of preoperative predictors for pouchitis after surgery for ulcerative colitis: a multicentre retrospective study of the clinical outcome of surgery for ulcerative colitis in Japan (COSUC study). Colorectal Dis. 2025;27(10):e70267.","journal-title":"Colorectal Dis"},{"issue":"7","key":"2383_CR91","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/apt.15997","volume":"52","author":"HT Kani","year":"2020","unstructured":"Kani HT, Ramai D, Caniglia E, Hudesman D, Axelrad J, Nicholson J, et al. Systematic review with meta-analysis: a history of smoking is not associated with a higher risk of pouchitis. Aliment Pharmacol Ther. 2020;52(7):1117\u201324.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2383_CR92","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/ecco-jcc\/jjad051","volume":"17","author":"MG Fadel","year":"2023","unstructured":"Fadel MG, Geropoulos G, Warren OJ, Mills SC, Tekkis PP, Celentano V, et al. Risks factors associated with the development of Crohn\u2019s disease after ileal pouch-anal anastomosis for ulcerative colitis: a systematic review and meta-analysis. J Crohns Colitis. 2023;17(9):1537\u201348.","journal-title":"J Crohns Colitis"},{"issue":"9","key":"2383_CR93","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S2468-1253(23)00154-1","volume":"8","author":"TL Parigi","year":"2023","unstructured":"Parigi TL, D\u2019Amico F, Abreu MT, Dignass A, Dotan I, Magro F, et al. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol Hepatol. 2023;8(9):853\u20139.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"6","key":"2383_CR94","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.cgh.2022.04.026","volume":"21","author":"EL Barnes","year":"2023","unstructured":"Barnes EL, Long MD, Raffals L, Isaacs K, Stidham RW, Herfarth HH, et al. Development of the endoscopic pouch score for assessment of inflammatory conditions of the pouch. Clin Gastroenterol Hepatol. 2023;21(6):1663\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"2383_CR95","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/j.cgh.2021.11.012","volume":"20","author":"JE Ollech","year":"2022","unstructured":"Ollech JE, Bannon L, Maharshak N, Bar N, Goren I, Tulchinsky H, et al. Fecal calprotectin is increased in pouchitis and progressively increases with more severe endoscopic and histologic disease. Clin Gastroenterol Hepatol. 2022;20(8):1839-46 e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2383_CR96","doi-asserted-by":"publisher","first-page":"367","DOI":"10.14309\/ajg.0000000000002038","volume":"118","author":"JE Ollech","year":"2023","unstructured":"Ollech JE, Yanai H, Avni-Biron I, Snir Y, Banai H, Barkan R, et al. Fecal calprotectin and quality of life questionnaires are responsive to change in pouch disease activity after antibiotic therapy: results from a prospective clinical trial. Am J Gastroenterol. 2023;118(2):367\u201370.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2383_CR97","doi-asserted-by":"publisher","first-page":"S-1128","DOI":"10.1016\/S0016-5107(26)02805-1","volume":"103","author":"G Syal","year":"2026","unstructured":"Syal G, Kwon Y, Garcia NJ, Nguyen PH, Park S, Li J, et al. Su1667 Endoscopic remission reduces the risk of treatment failure but not IBD-related hospitalizations or complications in patients with chronic pouchitis and Crohn\u2019s like disease of the pouch. Gastrointest Endosc. 2026;103(5):S-1128-S\u22129.","journal-title":"Gastrointest Endosc"},{"issue":"2","key":"2383_CR98","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.cgh.2022.01.033","volume":"21","author":"M Kayal","year":"2023","unstructured":"Kayal M, Kohler D, Colombel JF, Dubinsky MC, Ungaro RC. Early biologic initiation after chronic pouch inflammation diagnosis does not impact clinical outcomes. Clin Gastroenterol Hepatol. 2023;21(2):541-2 e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2383_CR99","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/gast.1999.0029900429","volume":"117","author":"E Ricart","year":"1999","unstructured":"Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Successful management of Crohn\u2019s disease of the ileoanal pouch with infliximab. Gastroenterology. 1999;117(2):429\u201332.","journal-title":"Gastroenterology"},{"issue":"10","key":"2383_CR100","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1046\/j.1365-2036.2003.01535.x","volume":"17","author":"A Viscido","year":"2003","unstructured":"Viscido A, Habib FI, Kohn A, Papi C, Marcheggiano A, Pimpo MT, et al. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther. 2003;17(10):1263\u201371.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"2383_CR101","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1111\/j.1572-0241.2003.07675.x","volume":"98","author":"JF Colombel","year":"2003","unstructured":"Colombel JF, Ricart E, Loftus EV Jr., Tremaine WJ, Young-Fadok T, Dozois EJ, et al. Management of Crohn\u2019s disease of the ileoanal pouch with infliximab. Am J Gastroenterol. 2003;98(10):2239\u201344.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2383_CR102","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1365-2036.2008.03656.x","volume":"27","author":"C Calabrese","year":"2008","unstructured":"Calabrese C, Gionchetti P, Rizzello F, Liguori G, Gabusi V, Tambasco R, et al. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment Pharmacol Ther. 2008;27(9):759\u201364.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2383_CR103","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ibd.21037","volume":"16","author":"M Ferrante","year":"2010","unstructured":"Ferrante M, D\u2019Haens G, Dewit O, Baert F, Holvoet J, Geboes K, et al. Efficacy of infliximab in refractory pouchitis and Crohn\u2019s disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis. 2010;16(2):243\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"2383_CR104","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/ibd.21821","volume":"18","author":"M Barreiro-de Acosta","year":"2012","unstructured":"Barreiro-de Acosta M, Garcia-Bosch O, Souto R, Manosa M, Miranda J, Garcia-Sanchez V, et al. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. Inflamm Bowel Dis. 2012;18(5):812\u20137.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"2383_CR105","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1016\/j.crohns.2013.02.018","volume":"7","author":"N Viazis","year":"2013","unstructured":"Viazis N, Giakoumis M, Koukouratos T, Anastasiou J, Katopodi K, Kechagias G, et al. Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis. J Crohns Colitis. 2013;7(10):e457\u201360.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"2383_CR106","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000438922","volume":"92","author":"M Uchino","year":"2015","unstructured":"Uchino M, Ikeuchi H, Bando T, Hirose K, Hirata A, Chohno T, et al. Clinical features of refractory pouchitis with penetrating lesions and the efficacy of infliximab treatment for patients with ulcerative colitis after restorative proctocolectomy. Digestion. 2015;92(3):147\u201355.","journal-title":"Digestion"},{"issue":"4","key":"2383_CR107","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/ecco-jcc\/jjv225","volume":"10","author":"OB Kelly","year":"2016","unstructured":"Kelly OB, Rosenberg M, Tyler AD, Stempak JM, Steinhart AH, Cohen Z, et al. Infliximab to treat refractory inflammation after pelvic pouch surgery for ulcerative colitis. J Crohns Colitis. 2016;10(4):410\u20137.","journal-title":"J Crohns Colitis"},{"issue":"9","key":"2383_CR108","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/00365521.2018.1496271","volume":"53","author":"JP Segal","year":"2018","unstructured":"Segal JP, Penez L, Mohsen Elkady S, Worley GHT, McLaughlin SD, Mullish BH, et al. Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective study. Scand J Gastroenterol. 2018;53(9):1051\u20138.","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"2383_CR109","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/2050640619871797","volume":"7","author":"B Verstockt","year":"2019","unstructured":"Verstockt B, Claeys C, De Hertogh G, Van Assche G, Wolthuis A, D\u2019Hoore A, et al. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience. United Eur Gastroenterol J. 2019;7(9):1215\u201325.","journal-title":"United Eur Gastroenterol J"},{"issue":"2","key":"2383_CR110","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/00365521.2022.2110383","volume":"58","author":"S Lindh","year":"2023","unstructured":"Lindh S, Bengtsson J, Kaczynski J. Is biologic therapy effective for antibiotic-refractory pouchitis? Scand J Gastroenterol. 2023;58(2):148\u201350.","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"2383_CR111","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/MEG.0b013e3283525a7b","volume":"24","author":"M Barreiro-de Acosta","year":"2012","unstructured":"Barreiro-de Acosta M, Garcia-Bosch O, Gordillo J, Manosa M, Menchen L, Souto R, et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol. 2012;24(7):756\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"2383_CR112","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/ibd.22933","volume":"18","author":"Y Li","year":"2012","unstructured":"Li Y, Lopez R, Queener E, Shen B. Adalimumab therapy in Crohn\u2019s disease of the ileal pouch. Inflamm Bowel Dis. 2012;18(12):2232\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"2383_CR113","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/apt.14479","volume":"47","author":"F Bar","year":"2018","unstructured":"Bar F, Kuhbacher T, Dietrich NA, Krause T, Stallmach A, Teich N, et al. Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis. Aliment Pharmacol Ther. 2018;47(5):581\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2383_CR114","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/gastro\/goy014","volume":"6","author":"F Khan","year":"2018","unstructured":"Khan F, Gao XH, Singh A, Philpott JR, Shen B. Vedolizumab in the treatment of Crohn\u2019s disease of the pouch. Gastroenterol Rep. 2018;6(3):184\u20138.","journal-title":"Gastroenterol Rep"},{"issue":"2","key":"2383_CR115","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/gastro\/goz001","volume":"7","author":"A Singh","year":"2019","unstructured":"Singh A, Khan F, Lopez R, Shen B, Philpott J. Vedolizumab for chronic antibiotic-refractory pouchitis. Gastroenterol Rep. 2019;7(2):121\u20136.","journal-title":"Gastroenterol Rep"},{"issue":"9","key":"2383_CR116","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/ibd\/izz030","volume":"25","author":"M Gregory","year":"2019","unstructured":"Gregory M, Weaver KN, Hoversten P, Hicks SB, Patel D, Ciorba MA, et al. Efficacy of vedolizumab for refractory pouchitis of the ileo-anal pouch: results from a multicenter US cohort. Inflamm Bowel Dis. 2019;25(9):1569\u201376.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"2383_CR117","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/ibd\/izy302","volume":"25","author":"KN Weaver","year":"2019","unstructured":"Weaver KN, Gregory M, Syal G, Hoversten P, Hicks SB, Patel D, et al. Ustekinumab is effective for the treatment of Crohn\u2019s disease of the pouch in a multicenter cohort. Inflamm Bowel Dis. 2019;25(4):767\u201374.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"2383_CR118","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.cgh.2024.04.030","volume":"22","author":"A Outtier","year":"2024","unstructured":"Outtier A, Louis E, Dewit O, Reenaers C, Schops G, Lenfant M, et al. Efficacy and safety of ustekinumab for chronic pouchitis: a prospective open-label multicenter study. Clin Gastroenterol Hepatol. 2024;22(12):2468-74 e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"2383_CR119","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/ibd\/izad191","volume":"30","author":"G Syal","year":"2024","unstructured":"Syal G, Mishkin DS, Banty A, Lee S, Fontelera N, Hampton M, et al. Effectiveness of oral tofacitinib in chronic pouchitis: a prospective, open-label pilot study. Inflamm Bowel Dis. 2024;30(10):1907\u201310.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"2383_CR120","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.dld.2023.04.028","volume":"55","author":"M Uzzan","year":"2023","unstructured":"Uzzan M, Nachury M, Amiot A, Peyrin-Biroulet L, Kirchgesner J, Bouhnik Y. Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologics. Dig Liver Dis. 2023;55(8):1158\u201360.","journal-title":"Dig Liver Dis"},{"issue":"9","key":"2383_CR121","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/ibd\/izad011","volume":"29","author":"S Akiyama","year":"2023","unstructured":"Akiyama S, Cohen NA, Kayal M, Dubinsky MC, Colombel JF, Rubin DT. Treatment of chronic inflammatory pouch conditions with tofacitinib: a case series from 2 tertiary IBD centers in the United States. Inflamm Bowel Dis. 2023;29(9):1504\u20137.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2383_CR122","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ueg2.12683","volume":"13","author":"DC de Jong","year":"2025","unstructured":"de Jong DC, Goetgebuer R, Muskens BLM, Neefjes-Borst EA, Gecse KB, Lowenberg m, et al. Tofacitinib for the treatment of chronic pouchitis: a pilot study. United Eur Gastroenterol J. 2025;13(2):201\u20139.","journal-title":"United Eur Gastroenterol J"},{"issue":"6","key":"2383_CR123","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s10350-004-0525-z","volume":"47","author":"MP Gosselink","year":"2004","unstructured":"Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum. 2004;47(6):876\u201384.","journal-title":"Dis Colon Rectum"},{"key":"2383_CR124","unstructured":"Brown S, Megan J, Smith S, Matchet D, Elliott R. Bifidobacterium longum BB-536 and prevention of acute pouchitis. Gastroenterology; 2004: WB Saunders Co Independence Square West Curtis Center, Ste 300, Philadelphia; 2004. p. A465-A."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02383-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02383-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02383-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:02:31Z","timestamp":1790366551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02383-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":124,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2383"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02383-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"27 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.F. and C.T. have no conflicts to declare; S.D. has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma, and Vifor. L.P-B. Declares consulting for: Abbvie, Abivax, Adacyte, Alimentiv, Alfasigma, Amgen, Apini, Banook, BMS, Boehringher, Celltrion, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, GSK, Hemay, Iterative Health, Janssen, Lilly, LifeMine, Luzsana, Medac, Mirador, Morphic, MSD, Nordic Pharma, Novartis, Oddifact, Oncodesign Precision Medicine, Coultreon (ex-Onco3R), ONO Pharma, OSE Immunotherapeuthics, Palisade Bio, Par\u2019 Immune, Pfizer, Prometheus, Roche, Roivant, Samsung, Sandoz, Sanofi, Sorriso, Spyre, Takeda, Teva, ThirtyfiveBio, Tillots, Vectivbio, Vedanta, and Ventyx. Stock options: Iterative Health, Oragen, and Pharmanest. Thetis lecture: Abbvie, Alfasigma, Amgen, Biogen, Celltrion, Dr Falk, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Iterative Health, Janssen, Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Roche, Sandoz, Takeda, and Tillots. V.J. has received consulting\/advisory board fees from AbbVie, Alimentiv, Asieris, AstraZeneca, Attovia, Biomebank, Boehringer Ingelheim, Caldera Therapeutics, Calluna, Celltrion, Domain Therapeutics, Eli Lilly, Enthera, Ensho, Exeliom Biosciences, Ferring Ventures, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Granite Bio, Janssen, Merck, Metacrine, Mountainfield, MRM Health, Nxera, Organon, OSE Immunotherapeutics, Pandion, Pendopharm, Pfizer, Prometheus Biosciences, Roche, Salvina, Sanofi, Shattuck Labs, Sorriso, Spyre, Synedgen, Takeda, Teva, Thabor Therapeutics, Union Therapeutics, Ventus, Ventyx, Vividion, Xencor, and Zealand. Pharma speaker\u2019s fees from, Abbvie, Ferring, Eli Lilly, Pfizer, and Takeda. R.S. has received consulting fees from: AbbVie, Alimentiv, Pendopharm, and Takeda. I.D. declares fees for consultation, advisory boards, honoraria for speaking and teaching, royalties, or grant support from Abbvie, Altman Research, AstraZeneca, BMS, Celltrion, Eli-Lilly, Falk Pharma, Ferring, Gilead, Galapagos, Roche\/Genentech, Harp Dx, Janssen, Pfizer, Prometheus Biosciences, Sandoz, Sangamo, Spyre Therapeutics, and Takeda. R.P. is a consultant for: Abbott, AbbVie, Abbivax, Alimentiv, Amgen, AnaptysBio, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Inviva, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mirador, Novartis, Oppilan Pharma, Odyssey, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Sanofi, Satisfai Health, Shire, Sublimity Therapeutics, Spyre Therapeutics, Takeda Pharmaceuticals, Teva, Tillots, Trellus, Union Biopharma, Viatris, Ventyx, and UCB. Speaker\u2019s Fees for:\u00a0AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Gilead Sciences, Janssen, Merck, Organon, Pfizer, Roche, Sandoz, Shire, and Takeda. Pharmaceuticals Advisory Boards for: AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Sanofi, Sublimity Therapeutics, Takeda Pharmaceuticals, and Ventyx. C.M. has recieved consulting fees: AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Forte Biosciences, Fresenius Kabi, Gilead, Janssen, McKesson, Mirador Therapeutics, Mylan, Pendopharm, Pfizer, Prometheus Biosciences Inc, Roche, Sanofi, Takeda, and Tillotts Pharma. Speaking fees: AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Bristol Myers Squibb, Eli Lilly, Ferring, Fresenius Kabi, Janssen, Merck, Organon, Pendopharm, Pfizer, Sanofi, Takeda, and Tillotts Pharma. Royalties: Springer Publishing research support from AbbVie, Eli Lilly, Ferring, and Pfizer.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I.F.: writing original draft, review, and editing\n                      ,\n                      C.T.: writing original draft, review, and editing\n                      ,\n                      S.D.: writing, review, and editing, L.P-B.: writing, review, and editing, V.J.: writing, review, and editing, R.S.: writing, review, and editing, I.D.: writing, review, and editing, R.P.: writing, review, and editing, C.M.: conceptualization, writing, review, and editing. All authors have read and approved the final version of the manuscript and agree to be accountable for the work.","order":2,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Availability of data and materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}